Ariad Pharmaceuticals, Inc.  

(Public, NASDAQ:ARIA)   Watch this stock  
Find more results forARIA
-0.02 (-0.11%)
After Hours: 23.66 -0.01 (-0.02%)
Jan 17, 4:18pm GMT-5  
NASDAQ real-time data - Disclaimer
Currency in USD
Range 23.64 - 23.72
52 week 4.37 - 23.81
Open 23.67
Vol / Avg. 13.05M/12.21M
Mkt cap 4,591.89M
P/E     -
Div/yield     -
EPS -0.18
Shares 194.20M
Beta 2.09
Inst. own 88%
Feb 21, 2017
Q4 2016 ARIAD Pharmaceuticals Inc Earnings Release (Estimated) - 9:30am GMT-5 - Add to calendar
Jan 9, 2017
ARIAD Pharmaceuticals Inc at JPMorgan Healthcare Conference
Dec 7, 2016
ARIAD Presents Data on Brigatinib from the World Conference on Lung Cancer Conference Call - Webcast
Nov 16, 2016
ARIAD Pharmaceuticals Inc at Jefferies Healthcare Conference - Webcast
Nov 7, 2016
Q3 2016 ARIAD Pharmaceuticals Inc Earnings Release
Nov 7, 2016
Q3 2016 ARIAD Pharmaceuticals Inc Earnings Call
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '16) 2015
Net profit margin -60.47% -194.57%
Operating margin -54.31% -182.89%
EBITD margin - -172.15%
Return on average assets -17.16% -40.21%
Return on average equity - -
Employees 459 -
CDP Score - -


125 Binney St
CAMBRIDGE, MA 02142-1123
United States - Map
+1-617-4940400 (Phone)
+1-617-4948144 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


ARIAD Pharmaceuticals, Inc. (ARIAD) is an oncology company. The Company is focused on transforming the lives of cancer patients with medicines. The Company's product pipeline includes Iclusig (ponatinib), brigatinib, AP32788 and ridaforolimus. The Company's Iclusig is a tyrosine kinase inhibitor (TKI) that is approved in the United States, the European Union, Australia, Switzerland, Israel and Canada for the treatment of adult patients with chronic myeloid leukemia (CML), and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). Its Brigatinib is an investigational inhibitor of anaplastic lymphoma kinase (ALK). Its AP32788 is a TKI, which is designed as a targeted therapy for patients with non-small cell lung cancer (NSCLC) with specific mutations in two kinases, epidermal growth factor receptor (EGFR), or human epidermal growth factor receptor 2 (HER2). Its Ridaforolimus is an investigational inhibitor of the mammalian target of rapamycin (mTOR).

Officers and directors

Alexander J. Denner Ph.D. Independent Chairman of the Board
Age: 46
Bio & Compensation  - Reuters
Paris Panayiotopoulos President, Chief Executive Officer, Director
Age: 42
Bio & Compensation  - Reuters
Manmeet S. Soni Chief Financial Officer, Executive Vice President, Treasurer
Age: 38
Bio & Compensation  - Reuters
Jennifer Lyn Herron Executive Vice President, Chief Commercial Officer
Age: 46
Bio & Compensation  - Reuters
Jayne M. Gansler Senior Vice President - Human Resources
Age: 61
Bio & Compensation  - Reuters
Daniel M. Bollag Ph.D. Senior Vice President - Regulatory Affairs and Quality
Age: 55
Bio & Compensation  - Reuters
Maria E. Cantor Senior Vice President - Corporate Affairs
Age: 48
Bio & Compensation  - Reuters
Hugh M. Cole Senior Vice President, Chief Business Officer
Age: 51
Bio & Compensation  - Reuters
Timothy P. Clackson Ph.D. President - Research and Development, Chief Scientific Officer
Age: 51
Bio & Compensation  - Reuters
George W. Bickerstaff III Independent Director
Age: 60
Bio & Compensation  - Reuters